Advanced Search

 

Study ID Status Title Patient Level Data
115575 Completed MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma Study Listed on ClinicalStudyDataRequest.com
115576 Completed An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne Study Listed on ClinicalStudyDataRequest.com
115578 Recruiting Post Marketing Surveillance (PMS) of safety and efficacy of Votrient in Korean patients
115579 Completed An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ALTARGO(retapamulin) administered in Korean patients according to the prescribing information
115588 Completed MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma Study Listed on ClinicalStudyDataRequest.com
115596 Completed RES115596: Estimation of Skeletal Muscle Mass with D3 Creatine Pharmacokinetic Study in Healthy Volunteers
115601 Completed A Phase I/II, Open-label Study of Ofatumumab added to Chlorambucil in Previously Untreated Japanese Patients with Chronic Lymphocytic Leukemia
115611 Active not recruiting ADA gene transfer into hematopoietic stem/progenitor cells for the treatment of ADA-SCID
115640 Completed A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipi
115642 Completed A Phase 1b, Randomized, Placebo Controlled, Crossover Study to Evaluate The Efficacy of GSK1440115 after a Single Oral Dose in Asthmatic Subjects
115645 Completed A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents with Asthma Study Listed on ClinicalStudyDataRequest.com
115646 Completed A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
115647 Completed A MULTICENTRE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS, SAFETY AND TREATMENT COSTS OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV INFECTED PATIENTS IN ROUTINE CLINICAL PRACTICE IN PORTUGAL
115648 Completed Consistency study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) (Priorix®) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine (M M R®II), in healthy children 12 to 15 months of age
115649 Completed Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s measles-mumps-rubella (MMR) vaccine when both are given on a 2-dose schedule to healthy children in their 2nd year of life
115650 Completed Safety and immunogenicity study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age
115658 Completed A randomised, double-blind, placebo controlled, inhaled single escalating and repeat dose study using an aqueous droplet inhaler to investigate the safety, tolerability and pharmacokinetics of GSK2339345. Study Listed on ClinicalStudyDataRequest.com
115661 Completed MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects who participated in the MEA115588 or MEA115575 trials Study Listed on ClinicalStudyDataRequest.com
115676 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment Study Listed on ClinicalStudyDataRequest.com
115677 Completed A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
115678 Completed An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects Study Listed on ClinicalStudyDataRequest.com
115679 Completed An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).
115696 Completed An Adaptive, Two part, Two period, Single Sequence, Drug Interaction Study between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers
115697 Completed A Phase I, open label, randomized, two cohort, two period, oneway study to evaluate the effect of Boceprevir and Telaprevir onDolutegravir pharmacokinetics in healthy adult subjects (ING115697)
115698 Completed A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Dolutegravir (GSK1349572) 50 mg twice daily in Opiate-Dependent, HIV Seronegative Adult Subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.